Sol-Gel reports Phase II data for Epsolay in rosacea

In February, Sol-Gel Technologies Ltd. (NASDAQ:SLGL) said once-daily Epsolay (formerly VERED) met the co-primary endpoints in a Phase II trial in 92 patients with rosacea. Data from the double-blind, U.S. trial were presented at the American Academy of Dermatology meeting in San Diego.

On the first co-primary endpoint, 37.5% of patients who received Epsolay 1% and 53.3% of patients who received Epsolay 5% had a ≥2-grade improvement in Investigator's Global Assessment (IGA) score at week 12 vs. 20% for vehicle. On the other co-primary endpoint, Epsolay 1% and Epsolay 5% both reduced the mean percent change in inflammatory lesion count from baseline to week 12 vs. vehicle...